Details for Patent: 9,074,254

« Back to Dashboard

Which drugs does patent 9,074,254 protect, and when does it expire?

Patent 9,074,254 protects BYSANTI and FANAPT and is included in two NDAs.

This patent has five patent family members in four countries.

Summary for Patent: 9,074,254

Title:	Method of predicting a predisposition to QT prolongation
Abstract:	The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Inventor(s):	Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
Assignee:	Vanda Pharmaceuticals Inc
Application Number:	US12/593,419
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,074,254
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,074,254

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-001	Feb 20, 2026		RX	Yes	Yes	9,074,254					METHOD FOR ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN ADULTS BY ADMINISTERING MILSAPERIDONE TO A PATIENT BY LOWERING THE DOSE AFTER DETERMINING THAT THE PATIENT HAS A GENETIC PREDISPOSITION FOR QT PROLONGATION
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-001	Feb 20, 2026		RX	Yes	Yes	9,074,254					METHOD FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING MILSAPERIDONE TO A PATIENT BY LOWERING THE DOSE AFTER DETERMINING THAT THE PATIENT HAS A GENETIC PREDISPOSITION FOR QT PROLONGATION
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-002	Feb 20, 2026		RX	Yes	No	9,074,254					METHOD FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING MILSAPERIDONE TO A PATIENT BY LOWERING THE DOSE AFTER DETERMINING THAT THE PATIENT HAS A GENETIC PREDISPOSITION FOR QT PROLONGATION
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-002	Feb 20, 2026		RX	Yes	No	9,074,254					METHOD FOR ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN ADULTS BY ADMINISTERING MILSAPERIDONE TO A PATIENT BY LOWERING THE DOSE AFTER DETERMINING THAT THE PATIENT HAS A GENETIC PREDISPOSITION FOR QT PROLONGATION
Vanda Pharms Inc	BYSANTI	milsaperidone	TABLET;ORAL	220358-003	Feb 20, 2026		RX	Yes	No	9,074,254					METHOD FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING MILSAPERIDONE TO A PATIENT BY LOWERING THE DOSE AFTER DETERMINING THAT THE PATIENT HAS A GENETIC PREDISPOSITION FOR QT PROLONGATION

Foreign Priority and PCT Information for Patent: 9,074,254

PCT Information
PCT Filed	March 28, 2008	PCT Application Number:	PCT/US2008/058791
PCT Publication Date:	October 09, 2008	PCT Publication Number:	WO2008/121899

International Family Members for US Patent 9,074,254

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2134873
Spain	2542967
Japan	2010522773
Japan	5586094
World Intellectual Property Organization (WIPO)	2008121899